125 related articles for article (PubMed ID: 20478730)
21. Dramatic resolution of respiratory symptoms with imatinib mesylate in patients with chronic myeloid leukemia presenting with lower airway symptoms resembling asthma.
Ramanujam D; McNicholl F; Furby D; Richardson D; Cuthbert RJ; McMullin MF
Leuk Lymphoma; 2009 Oct; 50(10):1721-2. PubMed ID: 19757309
[No Abstract] [Full Text] [Related]
22. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension.
ten Freyhaus H; Dumitrescu D; Bovenschulte H; Erdmann E; Rosenkranz S
Clin Res Cardiol; 2009 Apr; 98(4):265-7. PubMed ID: 19219392
[No Abstract] [Full Text] [Related]
23. Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel.
Yamazaki R; Aisa Y; Mori T; Iketani O; Ikeda Y; Okamoto S
Leuk Lymphoma; 2009 Apr; 50(4):670-2. PubMed ID: 19373671
[No Abstract] [Full Text] [Related]
24. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Murphy M; Close J; Lottenberg R; Rajasekhar A
Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
[No Abstract] [Full Text] [Related]
25. Dasatinib is effective in imatinib-resistant CML.
Cannell E
Lancet Oncol; 2007 Apr; 8(4):286. PubMed ID: 17431950
[No Abstract] [Full Text] [Related]
26. [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
Taïeb A; Constans J; Mahon FX
Rev Med Interne; 2008 Mar; 29(3):173-5. PubMed ID: 17597261
[No Abstract] [Full Text] [Related]
27. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
28. Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate.
Christoforidou A; Kotsianidis I; Margaritis D; Anastasiadis A; Douvali E; Tsatalas C
Am J Hematol; 2012 Jan; 87(1):131-2. PubMed ID: 21919038
[No Abstract] [Full Text] [Related]
29. Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantation.
Kovacsovics T; Maziarz RT
Curr Oncol Rep; 2006 Sep; 8(5):343-51. PubMed ID: 16901395
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of chronic myeloproliferative disease-unclassifiable (CMPD-U) with no chromosomal abnormalities by imatinib mesylate.
Iyama S; Matsunaga T; Sato T; Murase K; Araki N; Takimoto R; Kobune M; Sagawa T; Takayama T; Niitsu Y
Intern Med; 2008; 47(8):791-4. PubMed ID: 18421200
[TBL] [Abstract][Full Text] [Related]
31. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
Breccia M; Salaroli A; Serrao A; Zacheo I; Saracino R; Alimena G
Leuk Lymphoma; 2014 Jan; 55(1):204-6. PubMed ID: 23586870
[No Abstract] [Full Text] [Related]
32. Gastrointestinal stromal tumor (GIST) and imatinib.
Kubota T
Int J Clin Oncol; 2006 Jun; 11(3):184-9. PubMed ID: 16850124
[TBL] [Abstract][Full Text] [Related]
33. Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.
Cojbasić I; Macukanović-Golubović L
Vojnosanit Pregl; 2010 Oct; 67(10):802-6. PubMed ID: 21061842
[TBL] [Abstract][Full Text] [Related]
34. Imatinib does not impair gonadal function.
Chuah C
Leuk Res; 2012 Mar; 36(3):262-3. PubMed ID: 22129479
[No Abstract] [Full Text] [Related]
35. Which TKI should be recommended as initial treatment for CML in chronic phase?
Schiffer CA
Oncology (Williston Park); 2012 Oct; 26(10):912, 914. PubMed ID: 23175997
[No Abstract] [Full Text] [Related]
36. Treatment for plexiform neurofibromas in patients with NF1.
Ardern-Holmes SL; North KN
Lancet Oncol; 2012 Dec; 13(12):1175-6. PubMed ID: 23099008
[No Abstract] [Full Text] [Related]
37. Images in cardiology: Hypereosinophilic syndrome and effect of imatinib mesylate.
Jacob S; Kovacs RJ
Clin Cardiol; 2005 Apr; 28(4):188. PubMed ID: 15869052
[No Abstract] [Full Text] [Related]
38. Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance.
Sandoval C; Giamelli J; Jayabose S
J Pediatr Hematol Oncol; 2003 Jun; 25(6):507-8. PubMed ID: 12794534
[No Abstract] [Full Text] [Related]
39. Current management of GISTs.
Blanke C
Clin Adv Hematol Oncol; 2010 May; 8(5):334. PubMed ID: 20551892
[No Abstract] [Full Text] [Related]
40. The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones.
Gronchi A; Raut CP
Ann Surg Oncol; 2012 Apr; 19(4):1051-5. PubMed ID: 22207052
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
